Gilead Sciences Inc. (NASDAQ:GILD) is highlighted as one of the best stocks for the next decade, with Morgan Stanley raising the price target to $151 and an Overweight rating due to expected regulatory and political uncertainties to subside in the biopharma industry.

On December 15, Gilead Sciences Inc. (NASDAQ:GILD) reported positive results from its Phase 3 ARTISTRY-2 trial, showing non-inferiority of new regimen BIC/LEN to standard-of-care BIKTARVY in virologically suppressed adults with HIV-1, meeting primary efficacy endpoint at Week 48.

Gilead plans to use data from ARTISTRY-2 and ARTISTRY-1 trials for upcoming regulatory submissions, presenting detailed findings at a future scientific congress, marking a significant step in HIV innovation for the company.

Gilead Sciences Inc. (NASDAQ:GILD) is a biopharmaceutical company focusing on unmet medical needs in the US, Europe, and internationally, with a history of HIV innovation spanning 35 years.

Read more at Yahoo Finance: Morgan Stanley Expects Gilead Sciences (GILD) to Thrive as Biopharma Policy Uncertainties Fade in 2026